Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2012 1
2013 1
2017 1
2018 2
2020 2
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus.
Vang L, Morello CS, Mendy J, Thompson D, Manayani D, Guenther B, Julander J, Sanford D, Jain A, Patel A, Shabram P, Smith J, Alexander J. Vang L, et al. Among authors: mendy j. PLoS Negl Trop Dis. 2021 Mar 12;15(3):e0009195. doi: 10.1371/journal.pntd.0009195. eCollection 2021 Mar. PLoS Negl Trop Dis. 2021. PMID: 33711018 Free PMC article.
Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.
Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, Alexander J, Ledgerwood JE, de Lame PA, Royalty Tredo S, Warfield KL, Bedell L. Bennett SR, et al. Among authors: mendy j. Lancet Infect Dis. 2022 Sep;22(9):1343-1355. doi: 10.1016/S1473-3099(22)00226-2. Epub 2022 Jun 13. Lancet Infect Dis. 2022. PMID: 35709798 Clinical Trial.
Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.
Thompson D, Guenther B, Manayani D, Mendy J, Smith J, Espinosa DA, Harris E, Alexander J, Vang L, Morello CS. Thompson D, et al. Among authors: mendy j. PLoS Negl Trop Dis. 2022 Jul 6;16(7):e0010588. doi: 10.1371/journal.pntd.0010588. eCollection 2022 Jul. PLoS Negl Trop Dis. 2022. PMID: 35793354 Free PMC article.
Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge.
Malherbe DC, Vang L, Mendy J, Barnette PT, Spencer DA, Reed J, Kareko BW, Sather DN, Pandey S, Wibmer CK, Robins H, Fuller DH, Park B, Lakhashe SK, Wilson JM, Axthelm MK, Ruprecht RM, Moore PL, Sacha JB, Hessell AJ, Alexander J, Haigwood NL. Malherbe DC, et al. Among authors: mendy j. Front Immunol. 2021 Feb 15;11:626464. doi: 10.3389/fimmu.2020.626464. eCollection 2020. Front Immunol. 2021. PMID: 33658998 Free PMC article.
A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults.
Beaty S, Collins N, Karasavvas N, Kuschner R, Hang J, Adhikari A, Maljkovic Berry I, Fung C, Walls S, Betancourt E, Mendy J, Lock M, Gierman E, Bennett S, Shabram P, Warfield K. Beaty S, et al. Among authors: mendy j. Vaccines (Basel). 2023 Jun 12;11(6):1091. doi: 10.3390/vaccines11061091. Vaccines (Basel). 2023. PMID: 37376480 Free PMC article.
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
Chen GL, Coates EE, Plummer SH, Carter CA, Berkowitz N, Conan-Cibotti M, Cox JH, Beck A, O'Callahan M, Andrews C, Gordon IJ, Larkin B, Lampley R, Kaltovich F, Gall J, Carlton K, Mendy J, Haney D, May J, Bray A, Bailer RT, Dowd KA, Brockett B, Gordon D, Koup RA, Schwartz R, Mascola JR, Graham BS, Pierson TC, Donastorg Y, Rosario N, Pape JW, Hoen B, Cabié A, Diaz C, Ledgerwood JE; VRC 704 Study Team. Chen GL, et al. Among authors: mendy j. JAMA. 2020 Apr 14;323(14):1369-1377. doi: 10.1001/jama.2020.2477. JAMA. 2020. PMID: 32286643 Free PMC article. Clinical Trial.
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J. Malherbe DC, et al. Among authors: mendy j. J Virol. 2018 Jan 2;92(2):e01092-17. doi: 10.1128/JVI.01092-17. Print 2018 Jan 15. J Virol. 2018. PMID: 29093095 Free PMC article.
Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.
Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, Avanzini JB, Guenther B, Garduno F, Jow L, Snarsky V, Ishioka G, Dong X, Vang L, Newman MJ, Mayall T. Alexander J, et al. Among authors: mendy j. PLoS One. 2012;7(2):e31177. doi: 10.1371/journal.pone.0031177. Epub 2012 Feb 17. PLoS One. 2012. PMID: 22363572 Free PMC article.
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
Alexander J, Mendy J, Vang L, Avanzini JB, Garduno F, Manayani DJ, Ishioka G, Farness P, Ping LH, Swanstrom R, Parks R, Liao HX, Haynes BF, Montefiori DC, LaBranche C, Smith J, Gurwith M, Mayall T. Alexander J, et al. Among authors: mendy j. PLoS One. 2013 Dec 3;8(12):e82380. doi: 10.1371/journal.pone.0082380. eCollection 2013. PLoS One. 2013. PMID: 24312658 Free PMC article.
12 results